Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.24.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Condensed Consolidated Statements of Operations and Comprehensive Loss        
Revenues     $ 50  
Operating expenses:        
Research and development $ 1,535 $ 2,779 3,141 $ 5,327
General and administrative 2,961 7,794 6,508 12,882
Total operating expenses 4,496 10,573 9,649 18,209
Operating loss (4,496) (10,573) (9,599) (18,209)
Other income (expense):        
Interest expense (34) (31) (60) (31)
Interest income 42 41 97 140
Total other income 8 10 37 109
Net loss attributable to iBio, Inc. from continuing operations (4,488) (10,563) (9,562) (18,100)
Net loss from continuing operations (4,488) (10,563) (9,562) (18,100)
Loss from discontinued operations (3,723) (22,990) (4,395) (33,583)
Net loss (8,211) (33,553) (13,957) (51,683)
Comprehensive loss:        
Consolidated net loss (8,211) (33,553) (13,957) (51,683)
Other comprehensive loss - unrealized loss on debt securities   56   46
Comprehensive loss $ (8,211) $ (33,497) $ (13,957) $ (51,637)
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (2.42) $ (21.54) $ (6.27) $ (38.82)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (2.42) (21.54) (6.27) (38.82)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations (2.00) (46.89) (2.88) (72.03)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations (2.00) (46.89) (2.88) (72.03)
Loss per common share attributable to iBio, Inc. stockholders - basic - total (4.42) (68.43) (9.15) (110.85)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total $ (4.42) $ (68.43) $ (9.15) $ (110.85)
Weighted-average common shares outstanding - basic 1,856 490 1,525 466
Weighted-average common shares outstanding - diluted 1,856 490 1,525 466